Last reviewed · How we verify
low to intermediate 1 risk myelodysplastic syndromes mds with transfusion dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents esa
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- low to intermediate 1 risk myelodysplastic syndromes mds with transfusion dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents esa patent landscape — cliff calendar, originator estates, attackable patents
- low to intermediate 1 risk myelodysplastic syndromes mds with transfusion dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents esa treatment landscape brief
- low to intermediate 1 risk myelodysplastic syndromes mds with transfusion dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents esa treatment updates RSS
Related
- Treatment landscape: low to intermediate 1 risk myelodysplastic syndromes mds with transfusion dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents esa patent cliff · low to intermediate 1 risk myelodysplastic syndromes mds with transfusion dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents esa CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing